Inspiration Healthcare Group (IHC) Q2 2027 TU earnings summary

Executive summary

• Reported strong underlying growth across core product portfolio for the six months ended 31 July 2026, with continued momentum expected into the second half.

• Focused on building a sustainable and resilient growth platform, with a solid orderbook and pipeline of opportunities.

Financial highlights

• Revenues reached £22.0 million, compared to £24.0 million in H1 FY26, with the prior period benefitting from £6.5 million in one-off contract revenues.

• SLE product revenues were £12.7 million, representing 38% underlying growth over H1 FY26 when excluding prior year one-off contracts.

• Airon revenues increased by 40% to £1.6 million year-over-year.

• MedTech distribution revenues rose 7% to £7.6 million compared to H1 FY26.

• Net debt (excluding IFRS 16 lease liabilities) remained stable at £5.2 million as of 31 July 2026.

Outlook and guidance

• Entering the second half with confidence, a strong orderbook, and a robust pipeline.

• Expected to close the financial year slightly ahead of market expectations.

• Priorities include converting the pipeline, delivering sustainable profitable growth, and strengthening the financial position.